LOS ANGELES, Oct. 01, 2020 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus”) (CSE:VS) (OTCQB:VRSSF) (FRANKFURT:BMVA) today signed an agreement with Predictmedix, Inc. (“Predictmedix”) (CSE:PMED) (OTCQB:PMEDF), a medical software company that integrates Artificial Intelligence “AI” into healthcare testing technology. The agreement is to bring Versus’ proprietary rewards platform to the healthcare vertical – allowing healthcare providers, Contract Research Organizations (CROs), and life science companies to use rewards to recruit and retain a broader range of patients, and to promote compliance in testing medical therapies. These products, for use primarily by CROs, academic medical centers and those in the clinical trials markets, will enter a market that Fortune Business Insights estimates at $40 Billion USD annually.1
Predictmedix will use Versus’s patented rewards and engagement engine to incentivize users and patients to take steps in their treatment. In the case of clinical trials, this may include rewarding patients for joining certain trials, as well as for complying with trial protocols. According to Deloitte, recruiting, retention, and compliance are central issues in the clinical trial space with over 40% of patients not adhering to trial protocols.2 The Versus IP allows for remote data collection, real-time feedback, and a rewards-based engagement that could change patient behaviors and outcomes – saving time and money, and also improving healthcare outcomes by providing more complete trial data.
About Predictmedix, Inc.
Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. Predictmedix is developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious diseases for identification of symptomatic individuals.
Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, Predictmedix is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease. To find out more visit us at www.predictmedix.com
Disclaimer: “Predictmedix is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.”
For further information, please contact:
Dr. Rahul Kushwah, Chief Operating Officer
Tel: 647 889-6916
About Versus Systems
Versus Systems, Inc. has developed a proprietary in-game prizing and promotions engine that allows game publishers and developers to offer in-game and in-app prizing across mobile, console, PC games, and streaming media. Brands pay to place products in-game and gamers compete for those prizes. For more information, please visit www.versussystems.com or visit the official Versus Systems YouTube channel.
Disclaimer for Forward-Looking Information
This news release contains certain forward-looking information and forward-looking statements within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward looking statements. In this news release, forward-looking statements relate, among other things, to the inclusion of Versus’ proprietary rewards platform in the healthcare vertical under the agreement with Predictmedix, Inc. and the potential of improving healthcare outcomes through Versus’ IP by providing more complete trial data. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements and information. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward-looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this press release.